Pharnext fell by 10% on the Paris Bourse on Monday, following the announcement that the Global Tech Opportunities 13 fund had drawn down a new tranche of Océanes-BSA (OCABSA) for some 500,000 euros.

The biopharmaceutical company states that the OCABSA issue has enabled it to raise a total of 39.2 million euros, via the creation of 29.8 billion new shares.

The interest of a shareholder holding 1% of the capital prior to these drawdowns is now less than 0.0007%.

On Monday, Pharnext also announced a new timetable for negotiations aimed at increasing the value of its drug candidate for Charcot-Marie-Tooth type 1A disease.

Given the proximity of the first results from the pivotal Phase III
clinical study, scheduled for December 11, the company - which has received three offers to date - has decided not to sign an exclusivity agreement at this stage.

Copyright (c) 2023 CercleFinance.com. All rights reserved.